Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S117-21. Unique Identifier : AIDSLINE MED/95169466
Heeney JL; Holterman L; ten Haaft P; Dubbes R; Koornstra W; Teeuwsen V; Bourquin P; Norley S; Niphuis H; Laboratory of Viral Pathogenesis, Biomedical Primate Research; Center TNO, Rijswijk, The Netherlands.

Abstract: The efficacy of vaccine protection afforded by live attenuated vaccines was tested by heterologous SIVtno8980 challenge following successful protection against homologous SIVmac32H challenge. Animals immunized with the attenuated SIVmacBK28 molecular clone were asymptomatic and virus isolation negative by quantitative virus isolation prior to challenge. Two groups of four animals previously immunized 5 years and 4 months (respectively) were challenged with 100 MID50 of SIVtno8980, as was a third group of four naive controls. All control animals that were challenged developed high levels of plasma antigenemia within 2 weeks of challenge and developed rapid Th/m cell loss whereas vaccinated animals did not. Quantitative virus isolation from peripheral blood mononuclear cells revealed that one of four animals in each group became virus isolation positive but that the virus load in the two vaccinated animals was markedly lower than in nonvaccinated controls. Studies are underway to determine the duration and immunological correlates of protection from AIDS.
Keywords: Animal Immunization Macaca mulatta Neutralization Tests Simian Acquired Immunodeficiency Syndrome/IMMUNOLOGY/PREVENTION & CONTROL/VIROLOGY Species Specificity SAIDS Vaccines/*IMMUNOLOGY SIV/*IMMUNOLOGY/ISOLATION & PURIF Time Factors Vaccines, Attenuated/IMMUNOLOGY Vaccines, Synthetic/IMMUNOLOGY JOURNAL ARTICLEKWDanimalimmunizationmacacamulattaneutralizationtestssimianacquiredimmunodeficiencysyndrome/immunology/prevention&control/virologyspeciesspecificitysaidsvaccines/KWDimmunologysiv/KWDimmunology/isolation&puriftimefactorsvaccines,attenuated/immunologyvaccines,synthetic/immunologyjournalarticle
950630
M9561150

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .